Retrospective Cohort Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 28, 2023; 29(32): 4873-4882
Published online Aug 28, 2023. doi: 10.3748/wjg.v29.i32.4873
Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis
Huttakan Navadurong, Kessarin Thanapirom, Salisa Wejnaruemarn, Thaninee Prasoppokakorn, Roongruedee Chaiteerakij, Piyawat Komolmit, Sombat Treeprasertsuk
Huttakan Navadurong, Kessarin Thanapirom, Salisa Wejnaruemarn, Thaninee Prasoppokakorn, Roongruedee Chaiteerakij, Piyawat Komolmit, Sombat Treeprasertsuk, Division of Gastro-enterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand
Thaninee Prasoppokakorn, Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi 20110, Thailand
Author contributions: Navadurong H and Treeprasertsuk S designed the research, analyzed the data, and wrote the manuscript; Thanapirom K, Wejnaruemarn S, Prasoppokakorn T, Chaiteerakij R, and Komolmit P administered support; Navadurong H, Thanapirom K, Wejnaruemarn S, and Treeprasertsuk S provided the study materials; Navadurong H and Wejnaruemarn S collected and assembly the data.
Institutional review board statement: The study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No. 423/64).
Informed consent statement: The informed consent was waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sombat Treeprasertsuk, MD, PhD, Professor, Division of Gastro-enterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama 4 Road, Pathumwan District, Bangkok 10330, Thailand. battan5410@gmail.com
Received: May 21, 2023
Peer-review started: May 21, 2023
First decision: July 10, 2023
Revised: July 20, 2023
Accepted: August 9, 2023
Article in press: August 9, 2023
Published online: August 28, 2023
Processing time: 95 Days and 21.7 Hours
Core Tip

Core Tip: The albumin-bilirubin (ALBI) score has been successfully applied to the prediction of survival in patients with non-malignant liver diseases of various etiologies. This study demonstrated that the ALBI score can accurately identify decompensation risk at the 3-year follow-up in patients with compensated cirrhosis. The ALBI score is a simple and ready-to-use tool to help clinicians monitor and make appropriate treatment strategies in patients with compensated cirrhosis.